LLK203
LLK203 is a potent USP2/USP8 dual-target inhibitor with IC50s of 0.89 μM and 0.52 μM, respectively. LLK203 leads a degradation of ERα and induces apoptosis of breast cancer MCF-7 cells. LLK203 demonstrates antitumor activities against the 4T1 tumor mice model[1].
Product Specifications
CAS Number
2758090-62-7
UNSPSC
12352005
Target
Apoptosis; Deubiquitinase
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/llk203.html
Concentration
10mM
Purity
98.58
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(C1=CC=C(OC)C=C1NS(=O)(C2=CC=C(C3=CC=C(C)S3)C=C2)=O)NC4=NC(C5=CC=CC=C5)=CS4
Molecular Formula
C28H23N3O4S3
Molecular Weight
561.69
References & Citations
[1]Yucheng Tian, et al. The discovery of potent USP2/USP8 dual-target inhibitors for the treatment of breast cancer via structure guided optimization of ML364. European Journal of Medicinal Chemistry. Volume 268, 15 March 2024, 116275.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
USP2; USP8
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC040984-500 1x 500 µL
P21 / WAF1 (HJ21), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details